205
Participants
Start Date
June 19, 2013
Primary Completion Date
November 2, 2016
Study Completion Date
November 2, 2016
secukinumab 150 mg
Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consiseds of one secukinumab 150 mg s.c. injection plus one placebo secukinumab s.c. injection and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also received two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
secukinumab 300 mg
Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consisted of two secukinumab 150 mg s.c. injections and took ke place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also receives two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
Placebo
Placebo were provided in 1 mL pre-filled syringes. Each dosing consisted of two s.c. injections and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then at Week 8 and at Week 12. At Week 16, ppIGA responders continued on placebo with dosing at Weeks 16, 17, 18, 19 and 20, then once every four weeks from Week 24 until Week 76 inclusive. At Week 80, ppIGA responders ended their participation in the study while ppIGA non-responders were re-randomized, to receive 150 mg or 300 mg secukinumab once every four weeks starting at Week 80 until Week 128 inclusive. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
Novartis Investigative Site, Budapest
Novartis Investigative Site, Brussels
Novartis Investigative Site, Sydney
Novartis Investigative Site, East Melbourne
Novartis Investigative Site, Carlton
Novartis Investigative Site, Miskolc
Novartis Investigative Site, Liège
Novartis Investigative Site, Debrecen
Novartis Investigative Site, Stavanger
Novartis Investigative Site, Woolloongabba
Novartis Investigative Site, Breda
Novartis Investigative Site, High Point
Novartis Investigative Site, Gaziantep
Novartis Investigative Site, Tampere
Novartis Investigative Site, Fatih / Istanbul
Novartis Investigative Site, Istanbul
Novartis Investigative Site, Las Palmas de Gran Canaria
Novartis Investigative Site, Birmingham
Novartis Investigative Site, Louisville
Novartis Investigative Site, Indianapolis
Novartis Investigative Site, Petah Tikva
Novartis Investigative Site, Tel Aviv
Novartis Investigative Site, Phoenix
Novartis Investigative Site, Moscow
Novartis Investigative Site, Moscow
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Kazan'
Novartis Investigative Site, Afula
Novartis Investigative Site, Tel Aviv
Novartis Investigative Site, Boston
Novartis Investigative Site, Verona
Novartis Investigative Site, Goodlettsville
Novartis Investigative Site, Calgary
Novartis Investigative Site, Barrie
Novartis Investigative Site, London
Novartis Investigative Site, Waterloo
Novartis Investigative Site, Montreal
Novartis Investigative Site, Helsinki
Novartis Investigative Site, Szeged
Novartis Investigative Site, Amsterdam
Novartis Investigative Site, Rotterdam
Novartis Investigative Site, Coimbra
Novartis Investigative Site, Lisbon
Novartis Investigative Site, Lisbon
Novartis Investigative Site, Porto
Novartis Investigative Site, Porto
Novartis Investigative Site, Kosice-Saca
Novartis Investigative Site, Košice
Novartis Investigative Site, Svidník
Novartis Investigative Site, Badalona
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Ankara
Novartis Investigative Site, London
Novartis Investigative Site, Dudley
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY